Back to search results

TREE-Connect for Late-Life Depression

This study is looking at new ways to help people aged 50 to 80 who are experiencing depression. It compares two approaches: one uses remote therapy sessions along with a mental health app called TREE-Connect, and the other uses only remote therapy sessions. Both approaches aim to help you engage in more rewarding activities to improve your mood. To join, you should have mild to moderate depression symptoms and a good capacity to understand and consent to the study. The main goal is to see how acceptable these treatments are to participants after 9 weeks. We don't know yet if the study is actively enrolling participants.

Study design
This is an interventional study planning to enroll 60 participants. It is a randomized controlled trial comparing two different behavioral interventions.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for acceptability is measured at 9 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06910683

Technology dRiven Enhancement to Engage & Connect

Not Yet Recruiting
NAAges 50–80InterventionalTreatment
Weill Medical College of Cornell University
~60 participants
Updated 2026-03-24 on ClinicalTrials.gov
What's tested:TREE-ConnectClinician-delivered psychotherapy

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Acceptability (Client Satisfaction Questionnaire; CSQ)
Measured over 9 Weeks

Conditions

Depression

Explore related trials

Depression

NCT06910683

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Weill Cornell Medicine

    New York, New Yorkstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Nili Solomonov, PhD · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University
  • Samprit Banerjee, PhD · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University

Who to contact

Delaney Callaghan, BA
[email protected]
1-781-999-3731
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged 50-80
Capacity to provide consent for research assessment and treatment.
Significant depression, i.e., PHQ-9 ≥ 7 (mild-moderate severity of symptoms)
Mini Mental Status Exam (MMSE) equal or greater than a score of 23.
Off antidepressants or on stable dose for 8 weeks and do not intend to change the dose in the next 10 weeks, without individual psychotherapy services during the study period.

Exclusion

Intent or plan to commit suicide in the near future.
Inability to communicate in English.
History or presence of psychiatric diagnoses other than major depressive disorder without psychotic features, generalized anxiety disorder, specific phobia, or antisocial or borderline personality disorder.
Neurological disorders (dementias, amnestic and multidomain Mild Cognitive Impairment, Parkinson's disease, epilepsy, etc.).
Acute or severe medical illness in the past 3 months (metastatic cancer, multiple sclerosis, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction, cardiac, renal, or respiratory failure; severe chronic obstructive pulmonary disease, etc.) that may be the primary cause depressive symptoms, influence brain systems of interest, or impact ability to participate in the study.
For MRI only: Contraindications to MRI scanning including cardiac pacemaker, heart valve replacement, vascular stent, insulin pump, cochlear implant, any other metallic biomedical implant contraindicating to MRI, and claustrophobia.

What this trial measures

  • Acceptability (Client Satisfaction Questionnaire; CSQ)9 Weeks

    Acceptability will measured using the Client Satisfaction Questionnaire (CSQ) with a benchmar score of \>=3 (out of 4; average score); Range: 0 to 4, with higher scores indicating greater acceptability